Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
EBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsR&D In Process
Ratios

Zenas BioPharma (ZBIO) EBIAT (2023 - 2025)

Zenas BioPharma has reported EBIAT over the past 3 years, most recently at -$240.4 million for Q4 2025.

  • Quarterly results put EBIAT at -$240.4 million for Q4 2025, down 357.15% from a year ago — trailing twelve months through Dec 2025 was -$377.7 million (down 140.62% YoY), and the annual figure for FY2025 was -$377.7 million, down 140.59%.
  • EBIAT for Q4 2025 was -$240.4 million at Zenas BioPharma, down from -$51.5 million in the prior quarter.
  • Over the last five years, EBIAT for ZBIO hit a ceiling of $35.6 million in Q3 2023 and a floor of -$240.4 million in Q4 2025.
  • Median EBIAT over the past 3 years was -$38.3 million (2024), compared with a mean of -$52.4 million.
  • Peak annual rise in EBIAT hit 20.77% in 2025, while the deepest fall reached 357.15% in 2025.
  • Zenas BioPharma's EBIAT stood at -$24.6 million in 2023, then crashed by 113.56% to -$52.6 million in 2024, then crashed by 357.15% to -$240.4 million in 2025.
  • The last three reported values for EBIAT were -$240.4 million (Q4 2025), -$51.5 million (Q3 2025), and -$52.2 million (Q2 2025) per Business Quant data.